Altered protein processing including misfolding and aggregation is a frequent occurrence in aging neurons compared to younger cells. A number of neurological diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD) have been connected with increased misfolding and aggregation of specific proteins or peptides. Beta-amyloid (Abeta) is involved in the progression of AD through formation of extracellular amorphous plaques and neurotoxic fibrils, while alpha-synuclein is involved in the progression of PD through formation of intracellular fibrillar aggregates. Different variants and morphologies of Abeta and alpha-synuclein have been correlated with increased formation of the neurotoxic aggregates. Early detection and subsequent inhibition of neurotoxic aggregate formation can slow or stop the progression of such diseases. The long term goal of this project is to develop antibody fragments which can be used to identify critical protein morphologies which promote neurotoxic aggregate formation; and to engineer these antibodies so they can inhibit formation of these aggregates in vivo as a potential treatment. Phage display antibody libraries will be utilized to isolate pools of single chain antibody fragments (scFvs) which bind to particular morphologies of Abeta and alpha synuclein.
The specific aims of this proposal are to use phage display antibody libraries to; 1) isolate scFv antibody fragments specific to various lengths, conformations and morphologies of Abeta, 2) isolate scFvs specific to various morphologies of wild-type and mutant alpha-synuclein proteins, 3) identify which of these scFv antibodies can inhibit either Abeta or alpha-synuclein aggregation and fibril formation in vitro, which of these scFv antibodies can inhibit either Abeta or alpha-synuclein aggregation and fibril formation in vitro, and 4) increase the specificity of these antibodies as needed for imaging and inhibiting aggregation of Abeta or alpha- synuclein under in vivo conditions. Antibody specificity will be increased by subjecting the isolated parent antibody to random mutagenesis of targeted antibody blinding regions. From this pool of second generation antibodies, scFv fragments with increased specificity will be isolated. These high-specificity antibodies will be tested for their ability to inhibit formation of neurotoxic aggregates under in vivo conditions. Protein aggregation will be monitored using different techniques including Thioflavin T staining, atomic microscopy, and electron microscopy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG017984-04
Application #
6631468
Study Section
Special Emphasis Panel (ZAG1-PKN-8 (J1))
Program Officer
Snyder, Stephen D
Project Start
2000-05-01
Project End
2005-04-30
Budget Start
2003-05-01
Budget End
2005-04-30
Support Year
4
Fiscal Year
2003
Total Cost
$255,980
Indirect Cost
Name
Arizona State University-Tempe Campus
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
943360412
City
Tempe
State
AZ
Country
United States
Zip Code
85287
Marcus, Warren D; Wang, Hongda; Lindsay, Stuart M et al. (2008) Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy. Nanomedicine 4:1-7
Emadi, Sharareh; Barkhordarian, Hedieh; Wang, Min S et al. (2007) Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 368:1132-44
Marcus, Warren D; Lindsay, Stuart M; Sierks, Michael R (2006) Identification and repair of positive binding antibodies containing randomly generated amber codons from synthetic phage display libraries. Biotechnol Prog 22:919-22
Zameer, Andleeb; Schulz, Philip; Wang, Min S et al. (2006) Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry 45:11532-9
Barkhordarian, Hedieh; Emadi, Sharareh; Schulz, Philip et al. (2006) Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Des Sel 19:497-502
Liu, Ruitian; Barkhordarian, Hedieh; Emadi, Sharareh et al. (2005) Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis 20:74-81
Liu, Ruitian; Yuan, Bin; Emadi, Sharareh et al. (2004) Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43:6959-67
Liu, Ruitian; McAllister, Chad; Lyubchenko, Yuri et al. (2004) Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry 43:9999-10007
Emadi, Sharareh; Liu, Ruitian; Yuan, Bin et al. (2004) Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43:2871-8
Liu, Ruitian; McAllister, Chad; Lyubchenko, Yuri et al. (2004) Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. J Neurosci Res 75:162-71

Showing the most recent 10 out of 11 publications